New Molecule Targets Key Enzyme for Triple-Negative Breast Cancer Treatment
OHSU researchers developed SU212, a new molecule disabling the ENO1 enzyme. It significantly reduces triple-negative breast cancer growth and spread in mouse models, offering a promising therapy for this aggressive cancer and potentially other cancer types.